Oct. 19 (Bloomberg) -- Elan Corporation Plc said “key data” indicated patients on Tysabri experienced reduced annualized relapse rates, particularly in those treated early in the course of their disease.

To contact the editor responsible for this story: Dara Doyle at ddoyle1@bloomberg.net